These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 12144828

  • 1. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H, Naudé S.
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
    Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M.
    Hum Pathol; 2004 Jun; 35(6):745-51. PubMed ID: 15188142
    [Abstract] [Full Text] [Related]

  • 3. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
    Ciepliński K, Jóźwik M, Semczuk-Sikora A, Gogacz M, Lewkowicz D, Ignatov A, Semczuk A.
    Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
    [Abstract] [Full Text] [Related]

  • 4. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK, Grelewski P, Noga L, Rabczyński J, Gryboś M, Jeleń M.
    Adv Clin Exp Med; 2012 Feb; 21(1):35-42. PubMed ID: 23214297
    [Abstract] [Full Text] [Related]

  • 5. Expressions of proliferation markers (Ki-67, proliferating cell nuclear antigen, and silver-staining nucleolar organizer regions) and of p53 tumor protein in gestational trophoblastic disease.
    Kale A, Söylemez F, Ensari A.
    Am J Obstet Gynecol; 2001 Mar; 184(4):567-74. PubMed ID: 11262454
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
    Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N, Yoshida J.
    J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
    [Abstract] [Full Text] [Related]

  • 7. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome.
    Delahunt B, Bethwaite PB, Thornton A, Ribas JL.
    Cancer; 1995 Jun 01; 75(11):2714-9. PubMed ID: 7743475
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
    Mattila R, Alanen K, Syrjänen S.
    Arch Dermatol Res; 2007 Jan 01; 298(8):381-8. PubMed ID: 17072627
    [Abstract] [Full Text] [Related]

  • 10. Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53, and c-myc in differentiation and prognosis.
    de Rosa I, Staibano S, Lo Muzio L, Delfino M, Lucariello A, Coppola A, De Rosa G, Scully C.
    J Oral Pathol Med; 1999 Jul 01; 28(6):252-8. PubMed ID: 10426197
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA, Holli K, Kuukasjärvi T, Isola JJ.
    Br J Cancer; 1998 Jun 01; 77(12):2267-73. PubMed ID: 9649144
    [Abstract] [Full Text] [Related]

  • 12. Cell proliferation and p53 protein expressions in cutaneous epithelial neoplasms.
    Onodera H, Nakamura S, Sugai T.
    Am J Dermatopathol; 1996 Dec 01; 18(6):580-8. PubMed ID: 8989929
    [Abstract] [Full Text] [Related]

  • 13. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, Khatib G, Zeren H, Vardar MA, Altintas A.
    Arch Gynecol Obstet; 2014 Feb 01; 289(2):393-8. PubMed ID: 23974278
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. p53 protein overexpression, a frequent observation in squamous cell carcinoma of the vulva and in various synchronous vulvar epithelia, has no value as a prognostic parameter.
    Kagie MJ, Kenter GG, Tollenaar RA, Hermans J, Trimbos JP, Fleuren GJ.
    Int J Gynecol Pathol; 1997 Apr 01; 16(2):124-30. PubMed ID: 9100065
    [Abstract] [Full Text] [Related]

  • 18. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E.
    Br J Cancer; 1997 Apr 01; 75(9):1269-78. PubMed ID: 9155045
    [Abstract] [Full Text] [Related]

  • 19. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis.
    Guler N, Uckan S, Celik I, Oznurlu Y, Uckan D.
    Int J Oral Maxillofac Surg; 2005 Dec 01; 34(8):900-6. PubMed ID: 15907374
    [Abstract] [Full Text] [Related]

  • 20. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas.
    Suzuki T, Takano Y.
    Jpn J Cancer Res; 1993 Oct 01; 84(10):1072-7. PubMed ID: 7901190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.